UNSPSC 51384608: Difenamizole

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H22N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 24MR6YLL3W, chemically known as 1,3-diphenyl-5-(2-dimethylaminopropionamido)pyrazole but generally known as difenamizole, which bears US NIH Compound Identifier 65695. European Medicines Agency schedules Difenamizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07119MIG. The term DIFENAMIZOLE is an International Non-Proprietary Name.

UNSPSC 51384608 Difenamizole is a Commodity code that in practice captures state and local procurement of pharmaceutical products and drug-related supplies, though recent opportunities under this code show limited direct alignment with difenamizole specifically. The work actually being solicited includes naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing networks, and direct-to-manufacturer pharmacy benefit programs. Issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP), reflecting a mix of direct procurement by single jurisdictions and aggregated purchasing across multiple state and local member agencies.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: discrepancy in source dates). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. All three opportunities require vendors to meet federal compliance standards (cGMP, DSCSA, FDA requirements), maintain specified insurance coverage, and demonstrate EDI capability and pricing flexibility across multiple distribution channels.